Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Cetuximab + Irinotecan in Recurrent, Refractory and Metastatic Colorectal Cancer
NCT05143099Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in colorectal cancer (CRC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate at 24 months. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05143099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143099.